Home Tags Acorda Therapeutics
Tag: Acorda Therapeutics
Acorda Therapeutics is cutting its workforce by 15% and outsourcing certain unspecified operations, resulting in a savings of $20 million, according to the Ardsley-based...
The Westchester County Industrial Development Agency has given final approval of a $905,373 sales tax exemption for a $38 million renovation project at BioMed...
The Ardsley biotech company's inhalable form of L-dopa improved motor function in patients with re-emergent symptoms of Parkinson's Disease.
The Bill & Melinda Gates Foundation gives Acorda Therapeutics a $1.4 million grant to develop an inhaled treatment for infant respiratory distress syndrome.
Ron Cohen, president and CEO of Ardsley-based Acorda Therapeutics, is elected chairman of the board for the Biotechnology Industry Organization.
Based on a survey, Best Companies Group names Ardsley-based Acorda Therapeutics one of the best companies to work for in New York.
The Raw Beauty Project NYC photo exhibit at Acorda Therapeutics provides glimpses into the lives of women with spinal cord injuries.
Acorda Therapeutics posts earnings well above Wall Street expectations, while Regeneron and Progenics also post a profit.
Acorda Therapeutics Inc. in Ardsley expects to close in the fourth quarter on its cash acquisition of Civitas Therapeutics.
Regeneron Pharmaceuticals and Acorda Therapeutics post gains in earnings compared to the second quarter last year, while Progenics Pharmaceuticals sees a loss.
The Ardsley company alleges that Mylan Inc.'s application to get a generic form of the drug approved constitutes infringement of Acorda's patents.
12Page 1 of 2